Information Provided By:
Fly News Breaks for May 3, 2018
PCRX
May 3, 2018 | 12:52 EDT
Pacira Pharmaceuticals this morning posted solid Q1 Exparel sales of $74M, just ahead of the Street's $73.1M estimate and up over 9% year-on-year, H.C. Wainwright analyst Oren Livnat tells investors in a research note. He found it important that management highlighted strong intra-quarter growth trends with 6% growth in January accelerating to 15% in March. The analyst believes, however, that investors are concerned with no Exparel guidance increase and "confusing potential near-term Exparel reimbursement developments, or lack thereof." Livnat believes management is being conservative with the outlook and reiterates a Buy rating on Pacira with a $48 price target. The stock in midday trading is down 4% to $32.95.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.